Overview of Solid Lipid Nanoparticles in Breast Cancer Therapy

29Citations
Citations of this article
103Readers
Mendeley users who have this article in their library.

Abstract

Lipid nanoparticles (LNPs), composed of ionized lipids, helper lipids, and cholesterol, provide general therapeutic effects by facilitating intracellular transport and avoiding endosomal compartments. LNP-based drug delivery has great potential for the development of novel gene therapies and effective vaccines. Solid lipid nanoparticles (SLNs) are derived from physiologically acceptable lipid components and remain robust at body temperature, thereby providing high structural stability and biocompatibility. By enhancing drug delivery through blood vessels, SLNs have been used to improve the efficacy of cancer treatments. Breast cancer, the most common malignancy in women, has a declining mortality rate but remains incurable. Recently, as an anticancer drug delivery system, SLNs have been widely used in breast cancer, improving the therapeutic efficacy of drugs. In this review, we discuss the latest advances of SLNs for breast cancer treatment and their potential in clinical use.

Cite

CITATION STYLE

APA

Mo, K., Kim, A., Choe, S., Shin, M., & Yoon, H. (2023, August 1). Overview of Solid Lipid Nanoparticles in Breast Cancer Therapy. Pharmaceutics. Multidisciplinary Digital Publishing Institute (MDPI). https://doi.org/10.3390/pharmaceutics15082065

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free